With regard to the decision of Health Canada to issue a new decision on March 26, 2016, which imposed no terms and conditions on Apotex's Establishment Licenses for products fabricated at Apotex Pharmachem India Private Limited and Apotex Research Private Limited: (a) what new information did Health Canada receive that led to the new decision; (b) what is the title of the individual who made the new decision; (c) what are the details of any briefing documents or dockets prepared in relation to Apotex Inc. since November 4, 2015, including for each the (i) date, (ii) title or subject matter, (iii) the department’s internal tracking number; (d) was the Minister or any member of her exempt staff lobbied by Apotex and, if so, was this issue discussed; and (e) what are the details of any meetings Health Canada had with Apotex Inc. since November 4, 2015, including for each the (i) date, (ii) location, (iii) topics discussed, (iv) list of attendees?
In the House of Commons on November 3rd, 2017. See this statement in context.